Tata group’s Impetis out-licenses arthritis and autoimmune drugs to Vyome

In a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the US to license two cutting-edge experimental treatments. Focusing on challenges like rheumatoid arthritis and hair thinning, these selective JAK inhibitors are engineered to mitigate risks tied to earlier treatments.

Raccontata daeconomictimes.indiatimes.com